Thermo Fisher Scientific reported stronger‑than‑expected Q4 results and updated guidance for 2026, forecasting roughly 4–6% revenue growth as life sciences and bioprocessing demand remains healthy. The company said Q4 revenue climbed about 7% year‑over‑year and full‑year 2025 revenue topped $44.5 billion, driven by life‑sciences solutions and laboratory products and biopharma services. Management highlighted robust consumables demand in biologics manufacturing and steady instrument uptake. For biopharma customers, Thermo Fisher’s outlook signals continued spending on antibody production and analytical workflows—supporting downstream supply chains for therapeutic development and commercial supply.